About
FDA-cleared DL Precise™ produces consistent segmentation and measurement of masses in medical imaging across multiple imaging modalities (Ultrasound, Mammography, CT, MRI) – all with a single click. It consistently delineates using vivid color powered by DeepLook’s patented shape-recognition technology.
DL Precise data goes beyond the range of human vision, thereby improving clinician workflow and decision-making. The combination of DL Precise and our customers interfaces usher in a new era in oncological diagnosis and treatment. Implementation is quick and easy through the DL Precise application which can be downloaded to any Windows-based workstation via our customers interface in any medical workstation viewer. The display results of DL Precise can soon be sent to DeepLook’s new Cloud-based tumor library that will offer phenotype analysis and AI-driven correlations of the tumor features.
Enhanced vision is achieved by DeepLook Medical: Seeing is Believing.
Founders Bio
Marissa Fayer, CEO: 20+ year Medtech / women's health executive; Leader in women's health, Advocate, and Entrepreneur.
Greg Belanger, Founder and Chief Strategy Officer: 30+ year entrepreneur, and journalist, Co-Founder of DeepLook Medical.
David Dahn, CFO: 30-year finance professional focused on supporting early stage innovation.
Charlotte Moser, Chief Medical Officer: 20+ year MD/PhD/MBA in oncology and AI, CMO of Oncology and Pharma companies.
Paul Mullen, EVP Engineering: 38-year GE Healthcare Executive building the Ultrasound / Imaging business.
Product Overview
Honors and Awards
- AARP AgeTech Collborative Fall 2023 Cohort
- MassMedic MedTech Ignite Fall 2023 Cohort
- Portfolia+AARP Summer 2023 Winner
- HITLab Breaskthrough Alliance Finalist Summer 2023
- Women of Wearables FemTech finalist Spril 2023
- Well4Tech Fall 2022 Cohort
Materials